25,641 Shares in Smith & Nephew plc (NYSE:SNN) Purchased by Sanctuary Advisors LLC

Sanctuary Advisors LLC bought a new position in Smith & Nephew plc (NYSE:SNN) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 25,641 shares of the medical equipment provider’s stock, valued at approximately $627,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Nomura Holdings Inc. purchased a new stake in Smith & Nephew in the 4th quarter valued at about $887,000. Lorne Steinberg Wealth Management Inc. increased its stake in Smith & Nephew by 53.6% in the 2nd quarter. Lorne Steinberg Wealth Management Inc. now owns 231,045 shares of the medical equipment provider’s stock valued at $5,725,000 after buying an additional 80,650 shares during the last quarter. Clearbridge Investments LLC purchased a new stake in Smith & Nephew in the 1st quarter valued at about $2,612,000. Tocqueville Asset Management L.P. increased its stake in Smith & Nephew by 294.9% in the 1st quarter. Tocqueville Asset Management L.P. now owns 224,441 shares of the medical equipment provider’s stock valued at $5,692,000 after buying an additional 167,599 shares during the last quarter. Finally, Bank of Montreal Can increased its stake in Smith & Nephew by 355.8% in the 2nd quarter. Bank of Montreal Can now owns 1,235,916 shares of the medical equipment provider’s stock valued at $31,059,000 after buying an additional 964,762 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew Trading Up 0.7 %

Shares of SNN stock opened at $28.62 on Tuesday. The company has a 50 day moving average of $30.43 and a 200-day moving average of $27.43. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.11 and a current ratio of 2.51. Smith & Nephew plc has a 12-month low of $21.52 and a 12-month high of $31.72.

Wall Street Analysts Forecast Growth

SNN has been the subject of several analyst reports. StockNews.com upgraded shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research note on Monday, August 5th. Deutsche Bank Aktiengesellschaft started coverage on shares of Smith & Nephew in a research note on Wednesday, July 24th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy”.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.